NBIX
Neurocrine Biosciences Inc
142.30$
-1.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 171.0% | 239.3% | 0.8% | 1.1% | 0.9% | 1.0% | 1.3% | 1.6% | 2.1% | 1.4% | 1.8% | |
| – | 100.0% | 100.0% | 99.2% | 98.9% | 99.1% | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% | |
| – | 412.2% | 628.6% | 56.8% | 35.6% | 25.4% | 26.3% | 28.9% | 31.2% | 29.9% | 31.0% | 35.5% | |
| – | 164.3% | 453.9% | 105.1% | 55.2% | 44.9% | 41.4% | 51.5% | 50.6% | 45.1% | 34.7% | 40.4% | |
| – | 576.5% | 1,082.5% | 180.5% | 90.7% | 89.9% | 83.4% | 89.7% | 81.7% | 84.6% | 74.3% | 76.5% | |
| – | -476.5% | -982.5% | -81.3% | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% | |
| – | 0.0% | 0.0% | 12.1% | 6.8% | 4.1% | 3.1% | 2.3% | 0.5% | 0.2% | 5.4% | – | |
| – | -449.8% | -940.6% | -88.2% | 4.8% | 5.9% | 10.2% | 8.9% | 14.4% | 17.6% | 20.6% | 24.7% | |
| – | -31.7% | -51.5% | 10.6% | 0.2% | 1.2% | -28.7% | 1.0% | 4.0% | 4.4% | 6.1% | 7.9% | |
| – | -449.8% | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | |
| – | -444.7% | -930.9% | -74.6% | 9.1% | 10.9% | 14.2% | 12.2% | 17.8% | 22.0% | 27.2% | 23.3% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.